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Loss of the protein SMN causes spinal
muscular atrophy, but it is unclear why
deficiency in the ubiquitously expressed
protein primarily affects motor neurons.
In this study, Ng et al. show that a
hyperactive ER stress pathway in SMA
motor neurons could explain this
selective neuronal vulnerability.
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Spinal muscular atrophy (SMA) is caused by muta-
tions in the SMN1 gene. Because this gene is ex-
pressed ubiquitously, it remains poorly understood
why motor neurons (MNs) are one of the most
affected cell types. To address this question, we car-
ried out RNA sequencing studies using fixed, anti-
body-labeled, and purified MNs produced from con-
trol and SMA patient-derived induced pluripotent
stem cells (iPSCs). We found SMA-specific changes
in MNs, including hyper-activation of the ER stress
pathway. Functional studies demonstrated that inhi-
bition of ER stress improves MN survival in vitro even
in MNs expressing low SMN. In SMA mice, systemic
delivery of an ER stress inhibitor that crosses the
blood-brain barrier led to the preservation of spinal
cord MNs. Therefore, our study implies that selective
activation of ER stress underlies MN death in SMA.
Moreover, the approach we have taken would be
broadly applicable to the study of disease-prone hu-
man cells in heterogeneous cultures.
INTRODUCTION
Spinal muscular atrophy (SMA) is a genetic motor neuron (MN)
degenerative disease and is the leading genetic cause of infant
mortality. SMA is caused by mutations in the SMN1 gene, result-
ing in reduced levels of survival motor neuron (SMN) protein. This
causes the selective loss of spinal cord MNs and denervation of
skeletal muscles, eventually leading to muscular atrophy and
death. Humans contain two SMN genes (SMN1 and SMN2),
with the duplicated SMN2 gene behaving as a disease modifier
because it predominantly gives rise to an exon 7-skipped
mRNA that produces a truncated SMND7 protein together with
a small fraction of the full-length, functional SMN protein
(Burghes and Beattie, 2009). The severity of the disease is
inversely correlated with SMN protein levels, and it has beenCellwell established that loss of SMN function recapitulates the dis-
ease, whereas restoring full-length SMN protein reverses the
SMA phenotype (Corti et al., 2012; Ebert et al., 2009; Foust
et al., 2010). However, it remains unclear why the loss of SMN,
a ubiquitously expressed protein, results in the selective death
of MNs. This raises the possibility that MNs possess unique
properties that render them more sensitive to low levels of
SMN. The question of cell type selectivity underlies many neuro-
degenerative diseases, and the use of induced pluripotent stem
cells (iPSCs) now makes it possible to begin to understand how
this is achieved. Disease-relevant cell types can be derived from
patients and control subjects by directed differentiation of these
iPSCs, providing an in vitro platform for the discovery of disease-
associated phenotypes. However, these studies are often
complicated by the fact that neuronal cultures tend to be quite
heterogeneous. For example, MN cultures are ‘‘contaminated’’
by the presence of other types of spinal cord neurons and glial
cells. In some ways this is advantageous because it preserves
a more in vivo-like environment. Nonetheless, the presence of
other cells complicates the identification of specific changes
that might occur preferentially in MNs for which there are no
known cell surface markers to allow their purification by flow
cytometry.
To address the MN-specific degeneration in SMA, we used a
method to purify MNs based on intracellular protein labeling
(Hrvatin et al., 2014). Through RNA sequencing (RNA-seq) of
purified MNs, we identified gene expression changes in normal
versus SMA MNs. Gene clustering revealed that SMA MNs ex-
press high levels of apoptotic genes as well as genes involved in
the ER stress pathway. We also found that loss of SMN specif-
ically activates the unfolded protein response (UPR) in the MN
population, which may be somewhat surprising because SMA
is one of the few neurodegenerative diseases not characterized
by protein misprocessing and aggregate formation. It appears
that MNs are chronically more susceptible to ER stress (Kiskinis
et al., 2014) and that the loss of SMN further exacerbates this
condition. Notably, small-molecule antagonists of the ER stress
pathway promote SMA MN survival both in vitro and in vivo and
partially rescues the SMA phenotype without changing SMN
levels. Our data indicate that the UPR is selectively activated
in SMN-deficient MNs, eventually leading to motor neuronStem Cell 17, 569–584, November 5, 2015 ª2015 Elsevier Inc. 569
Figure 1. MNs Differentiated from SMA iPSCs Show Increased Apoptosis and Have Smaller Cell Bodies
(A) Differentiation scheme of iPSCs to MNs in 31 days.
(B) MN cultures at day 23, showing that both wild-type (BJ-riPS) and SMA type I (1-38G) iPSCs differentiate intoMNs expressing ISL1 and TUJ1. Many ISL1+ cells
also co-express HB9, another MN transcription factor. Scale bars, 50 mm.
(C) Percentage overlap between ISL1 and HB9 expression in MNs assessed by immunostaining. The percentages of ISL1+/HB9, ISL1+/HB9+, and ISL1/HB9+
MNs were similar between wild-type and SMA iPSC-derived cultures.
(D) Immunostaining showing HB9+ and/or ISL1+ co-expressing ChAT on day 28.
(E) Quantification of HB9+ MNs co-expressing ChAT on days 28 and 31.
(legend continued on next page)
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death. This study also serves as a proof of principle that intra-
cellularly based sorting strategies can be applied to understand
the pathogenesis of human diseases affecting selective cell
types.
RESULTS
MNs Generated from SMA Patient iPSCs Show a Pro-
Apoptotic Phenotype
We generated iPSCs from primary fibroblasts from a type I
SMA patient (1-38G) and a type II individual (1-51N). Both
type I and type II iPSCs displayed embryonic stem cell
morphology and expressed the pluripotency markers OCT4,
NANOG, and SOX2 (Figures S1A and S1B). Additional charac-
terization of these iPSCs will be available in a separate manu-
script. As controls, two wild-type iPSC lines, BJ-riPS (Warren
et al., 2010) and 18a (Boulting et al., 2011), reprogrammed
from neonatal foreskin fibroblasts and unaffected adult skin fi-
broblasts, respectively, were used. Although the severe type I
(1-38G) cultures express approximately 10% of the full-length
SMN protein, type II (1-51N) cultures retain about 30% of full-
length SMN protein compared with wild-type cell lines (Fig-
ure S1C). Using established protocols (Amoroso et al., 2013;
Yang et al., 2013), we generated MNs from both SMA and
wild-type iPSCs (Figure 1A; Supplemental Experimental Proce-
dures). By day 23 of differentiation, MNs expressing the
pan-neuronal marker TUJ1 and the MN-specific transcription
factors ISL1 and HB9 were formed (Figure 1B). By day 28,
some choline acetyltransferase (ChAT) expression was de-
tected in the MN cultures, and, overall, about 38% of all MNs
expressed ISL1 alone, 30% expressed HB9 alone, and 32%
of all MNs co-expressed ISL1 and HB9 (Figure 1C), consistent
with the in vivo distribution of single- and double-positive MNs
(Amoroso et al., 2013). By day 31, the majority (more than 80%)
of the ISL1+ and HB9+ MNs also co-expressed ChAT (Figures
1D–1F), an indication of MN maturity.
To reveal disease phenotypes associated with SMA iPSC-
derived MNs (Corti et al., 2012; Ebert et al., 2009), we measured
basal MN survival by counting ISL1+, HB9+, and ChAT+ MNs
from day 28, where ChAT expression was observed (Figure 1D),
to day 31. To eliminate dividing progenitors that could give rise to
new MNs over this time, cytosine arabinoside (AraC) treatment
was included from days 18–23 (Figure 1A). By day 31, a signifi-
cant decrease in MN survival was observed in the SMA cultures
compared with the wild-type MNs (Figures 1G–1J). We found
that both ISL1+ and HB9+ MNs were vulnerable in SMA iPSC-
derived cultures, with approximately 50% of type I MNs and
40% of type II MNs lost during the 3-day period, whereas only
an insignificant 20% of wild-type MNs were lost during that(F) Quantification of ISL1+ MNs co-expressing ChAT at days 28 and 31.
(G–J) Quantification of respective ISL1+, HB9+, ISL1+ and/or HB9+ and ChAT+MN
cultures on days 28 and 31. Numbers are shown as percentages normalized to t
(K) Representative images of BJ-riPS- and 1-38G-derived MNs co-stained with
measured soma sizes.
(L) Measurements of ISL1+ MN soma sizes on days 23 and 31. On day 23, the
230 mm2. By day 31, wild-type MNs remained the same size, whereas SMA MNs
(M) Measurements of healthy (ISL1+cCASP3) MN soma sizes and apoptotic (I
significantly smaller regardless of genotype (about 165 mm2) and that non-apopt
Error bars show SD of the mean. *p < 0.05, **p < 0.01, ***p < 0.001. n.s., not sig
Celltime (Figures 1G–1J). Of note, the percentage of non-MNs,
regardless of genotype, remained largely unchanged during
this time (Figure S1D), recapitulating a key feature of the disease
where selective MN death occurs.
Next, to assess the degree of cell death by apoptosis, immu-
nostaining of cleaved Caspase-3 (cCASP3) was performed at
day 28, and this revealed increased apoptosis in SMA MN cul-
tures compared with wild-type cultures, with approximately
20% of type I, 10% of type II, and 5% of wild-type MNs stained
positively for cCASP3 (Figures S1E and S1F). Supporting our
previous observations that both ISL1+ and HB9+ MNs are
equally affected in SMA, we found the percentages of apoptotic
ISL1+HB9 MNs, ISL1HB9+ MNs, and ISL1+HB9+ MNs to be
similar (Figure S1G). Notably, apoptotic rates of non-MNs in
wild-type and SMA cultures were low and indistinguishable
(approximately 6.5% of cCASP3+ISL1 cells) (Figure S1H). To
further ascertain that SMA MN cultures are less viable in vitro,
we determined the soma size of MNs (Figures 1K and 1L).
Although both wild-type and SMA MNs have similar cell body
sizes in the range of 220 mm2 at day 23 (Figure 1L), SMA MNs
are significantly smaller (decreasing to approximately 180 mm2)
by day 31 (Figures 1L and 1M). We also measured soma sizes
of apoptotic cCASP3+ MNs and found that they were indeed
much smaller than healthy cCASP3 MNs, measuring 165 mm2
regardless of whether they are wild-type or SMA MNs (Fig-
ure 1M). Because soma size is an indication of overall neuronal
health, the presence of smaller MNs, even among the non-
apoptotic MNs, appears to be a disease phenotype associated
with SMA.
RNA Sequencing of FACS-Purified MNs Reveals
MN-Specific Changes
Because MNs account for only about 20% of all cells in iPSC-
derived cultures and differentiation efficiencies vary from cell
line to cell line, gene expression analysis of whole unpurified cul-
tures will mask important MN-specific events. However,
because surface marker purification methods for MNs were un-
available, we used the method for analysis of RNA following
intracellular sorting (MARIS) technique (Hrvatin et al., 2014) to
obtain a pure HB9+MN population from day 31 cultures because
the transcription factor HB9 is one of the more specific markers
for human MNs (Amoroso et al., 2013). Briefly, cultures were di-
gested into single cells, fixed in paraformaldehyde, and incu-
bated with a specific HB9 antibody in a mild permeabilization/
blocking buffer before flow cytometry. Cells marked positive
for HB9 were then collected (Figure 2A). Total RNA extracted
from these fluorescence-activated cell sorting (FACS)-sorted
HB9+ cells remained intact (Figure 2B), and qPCR validation
confirmed high enrichment of the HB9 mRNA in the sortednumbers fromwild-type (BJ-riPS), SMA type I (1-38G), and SMA type II (1-51N)
he respective MN count on day 28.
ISL1 and TUJ1 on days 23 and 31. The white dotted outlines represent the
soma sizes of wild-type and SMA MNs were similar—between 210 mm2 and
were significantly smaller.
SL1+cCASP3+) MN soma sizes on day 31 showing that apoptotic MNs were
otic SMA MNs remained smaller compared with the wild-type counterparts.
nificant. See also Figure S1.
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Figure 2. Genome-wide RNA Sequencing of Fixed, Antibody-Labeled, and FACS-Purified MNs
(A) Schematic of the MN purification procedure by MARIS. MN cultures were digested into single cells, fixed, and permeabilized before incubation with a specific
HB9 antibody. HB9+ cells were sorted and collected. After reversal of crosslinks by proteinase K, RNA was isolated. SSC, side scatter.
(B) A representative Bioanalyzer trace showing the 18S and 28S rRNA peaks from RNA isolated by MARIS. An RNA integrity number (RIN) of more than 7.5
indicates intact RNA. FU, fluorescent unit.
(C) qPCR analysis showing enrichment of MNmarkers in the HB9+ sorted fraction compared with HB9 cells. As a control, the HUES3 HB9:GFP reporter cell line
was used, and fold changes were normalized to HB9:GFP-negative cells. Error bars show SD of the mean.
(D) Transcriptome analysis revealed 911 differentially expressed genes (fold change cutoff = 1.5, p < 0.01) in SMA MNs compared with wild-type MNs, with the
majority being upregulated in SMA MNs.
(E) Selected enriched reactome gene sets elucidated by GSEA. Gene sets related to the ER stress pathway are highlighted.
(F) Selected genes related to the ER stress pathway that are upregulated in SMA MNs. Their respective fold changes measured by RNA-seq are as shown.
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2 and Table S1.fraction. In addition, the MN markers ISL1 and ChAT were en-
riched significantly, whereas non-MN markers such as LMX1a
and S100B were depleted significantly in our purified MN RNA
samples (Figure 2C). Therefore, to identify cellular pathways
that are dysregulated specifically in SMA MNs, we performed
massively parallel RNA sequencing to measure global gene
expression of HB9+-purified MNs from SMA and wild-type
samples.572 Cell Stem Cell 17, 569–584, November 5, 2015 ª2015 Elsevier InSMA MNs Display Elevated Levels of ER Stress
RNA sequencing of purified wild-type and type I SMA MNs re-
vealed 911 differentially expressed mRNAs (fold change cutoff =
1.5; p < 0.01), of which 740 were upregulated and 171 downre-
gulated in SMAMNs (Figure 2D; Table S1). To investigate cellular
pathways that are modified in SMAMNs, we performed gene set
enrichment analysis (GSEA) (Subramanian et al., 2005) and iden-
tified 81 gene sets that were induced significantly in SMA MNsc.
(normalized enrichment score [NES] > 1.5) relative to wild-type
MNs. Gene sets that were enriched in SMA MNs include terms
related to apoptosis (Figure 2E), which we expected from the
MN viability studies (Figures S1E–S1G). We also found that
gene sets related to ER stress, such as association of the chap-
eronin complex TRiC/CCT with target proteins, protein folding,
and the ER/phagosome pathway, were enhanced in SMA MNs
(Figure 2E). Conversely, we observed depletion of specific
gene sets in SMA MNs, including gene sets associated with
the extracellular matrix, neurite outgrowth, and ion channels
(Figure 2E), all of which are important in neuronal function, syn-
aptogenesis, and development of the neuromuscular junction
(Singhal and Martin, 2011).
Because the pathology of SMA has not been linked previously
to unfolded proteins and protein aggregates, we wondered
about the relationship between SMN and the ER stress pathway.
To expand upon the finding that the UPR and the ER stress
pathway are associated with SMA MNs, we further analyzed
our RNA-seq results and identified the upregulation of numerous
heat shock proteins (HSPA4L, HSPB11, HSP90AB1, DNAJC12,
DNAJC18, DNAJC24, HSBP1, and DNAJA2), prefoldin subunits
(PFDN4, PFDN5, and PFDN6), chaperonin subunits (CCT3,
CCT4, CCT5, CCT6A, CCT7, and CCT8), as well as protein disul-
fide isomerases that modulate protein folding (PDIA3 and PDIA6)
in type I SMA MNs (Figure 2F), suggesting the activation of the
UPR pathway in these MNs.
To confirm the upregulation of UPR genes in SMA MNs, qRT-
PCRwas performed on FACS-purified HB9+MNs fromwild-type
(18a and BJ-riPS) and SMA cell lines (1-38G and 1-51N). We saw
a significant upregulation of the UPR target genes BiP (2.3-
fold), spliced XBP1 or sXBP1 (between 2- and 3.2-fold), and
ATF6 (>2-fold) in both type I and type II MNs compared with
wild-type MNs, with the more severe type I MNs generally
showing a bigger fold increase. Elevated levels of IRE1, PERK,
CHOP, and CASP3 were observed only in type I (1-38G) MNs
(Figure 3A), suggesting that these undergo more chronic ER
stress, leading to greater activation of the pro-apoptotic
branches of the UPR pathway.
In addition, the gene expression profiles of ISL1+MNs from the
wild-type and SMA cell lines were also analyzed. ISL1+ MNs
were highly enriched for MN markers (Figure S2A), similar to
what was observed for HB9+MNs (Figure 2C). Higher expression
levels of the UPR markers BiP (2-fold), sXBP1 (between 2- and
4-fold), and ATF6 (2.1-fold) were also observed (Figure S2B).
Just as what was observed in the purified HB9+ MNs, type I
ISL1+MNs generally expressed higher levels of ER stress genes.
Importantly, these changes in gene expression were not
observed when whole unpurified cultures were analyzed, con-
firming that these are MN-specific changes in SMA (Figure S2C),
and this underscores the importance of purifying MNs for tran-
scriptome analysis.
To expand upon our findings based on transcriptome analysis,
we then performed a series of immunostaining experiments to
measure the ER stress response in MNs and other non-MN cells
in the day 31 cultures by quantifying levels of the nuclear tran-
scription factors ATF6 and ATF4. Upon induction of ER stress,
ATF6, which is normally sequestered in the ER membrane, is
cleaved to give a truncated 50-kDa protein that translocates to
the nucleus to activate downstream UPR genes such as ERCellchaperones and folding catalysts that promote protein folding
(Hetz, 2012). We found that nuclear ATF6 intensity in MNs was
consistently higher than in non-MNs in all cultures (Figure 3B),
re-affirming that MNs undergo more basal ER stress than other
cells in culture (Kiskinis et al., 2014). More importantly, ISL1+
MNs from SMA cultures (1-38G and 1-51N) show a significantly
stronger nuclear ATF6 intensity compared with wild-type MNs,
with type I (1-38G) MNs having 150% more nuclear ATF6 (p =
0.0039) and type II (1-51N) MNs having 60% more nuclear
ATF6 (p = 0.0047) compared with wild-type MNs (Figure 3B).
Non-MNs (ISL1 cells) from the SMA cultures also show
increased nuclear ATF6 intensity compared with wild-type con-
trols, although this difference is smaller (Figure 3B), suggesting a
MN-selective sensitivity to low SMN levels.
Next, wemeasured the percentage of cells that express ATF4,
a transcription factor activated by the PERK pathway of the UPR
(Hetz, 2012). Analysis of day 31 cultures revealed a significant in-
crease in ATF4-expressing cells in SMA cultures (a more than
5-fold increase, p = 0.008) compared with controls. In addition,
approximately 36% of 1-38G MNs also co-express ATF4,
whereas 13% of 1-51N MNs are ATF4+ compared with less
than 5% in wild-typeMNs (Figure 3C). Collectively, the transcrip-
tome analysis of purified MNs, as well as quantitative ATF6 and
ATF4 immunostaining data, confirm that SMA MNs exhibit the
signature of high ER stress levels, with type I MNs being the
most affected.
ER Stress Increases in Mature MNs but Is Not Caused
by Apoptosis
Wenext investigated whether there is a relationship betweenMN
maturity and ER stress and, concomitantly, cell death. We per-
formed immunostaining experiments at three distinct time points
ofMNdifferentiation andmaturation (days 23, 28, and 31) and re-
vealed that the percentage of ATF4+MNs increased in SMAMNs
but not in wild-type MNs over time (Figure 3D). On day 28, there
were significantly more type I SMA MNs expressing ATF4 (15%
compared with < 1% in wild-typeMNs), and a similar percentage
stained positively for cCASP3. By day 31, the percentage of
ATF4+ type I MNs increased to 28%, and ATF4+ type II MNs
increased significantly to 17%, whereas less than 1% of wild-
type MNs were ATF4+ (Figure 3D). A similar trend for cCASP3+
apoptotic MNs followed, with increasing cCASP3+ MNs over
time and the severe type I MNs most affected (Figure 3E). We
also found that, of the ATF4+ MNs, a vast majority (83%)
were ChAT+ (Figure 3F), indicating that mature ChAT+ MNs
were more likely to undergo ER stress activation.
The observation that type IMNs, which express the least SMN,
have the highest expression levels of UPR genes (Figures 3A–
3C; Figure S2B) suggests that low SMN protein triggers ER
stress activation or that the ER stress response is activated in
dying cells regardless of SMN expression levels. First, to deter-
mine whether the UPR is activated in apoptotic cells, we treated
wild-type MN cultures with soluble Fas ligand (FasL) to induce
apoptosis through the death receptor signaling pathway (Raoul
et al., 1999; Ugolini et al., 2003). A 48-hr treatment with FasL
significantly increased apoptotic MNs from 6.2% to 14.8% (Fig-
ures S3A and S3D). However, nuclear ATF6 intensity and the
percentage of ATF4+ MNs remained unchanged (Figures S3B,
S3C, S3E, and S3F). In addition, gene expression analysis alsoStem Cell 17, 569–584, November 5, 2015 ª2015 Elsevier Inc. 573
(legend on next page)
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confirmed that cells treated with FasL did not affect key UPR
genes such as BiP, PERK, and CHOP (Figure S3G), indicating
that the UPR is not necessarily activated in apoptotic cells.
SMN Depletion Induces ER Stress in a Dose-Dependent
Manner
Next, to investigate the relationship between SMN and ER
stress, we performed small interfering RNA (siRNA)-mediated
knockdown of SMN in wild-type MNs. By transfecting different
amounts of siRNAs targeting the SMN mRNA, we were able to
achieve varying degrees of SMN knockdown (Figures 3G and
3H). By qPCR, the largest SMN knockdown, si-SMN (20 pmol),
resulted in the greatest induction of UPR target genes compared
with a non-targeting siRNA (si-NT), whereas the least efficient
SMN knockdown, si-SMN (5 pmol), caused only a slight increase
(less than 2-fold) in ATF6, IRE1, and CHOP mRNA (Figure 3G).
Similarly, increased levels of the 50-kDa cleaved ATF6 protein
were detected under the si-SMN (10 pmol) and si-SMN
(20 pmol) conditions, whereas the pro-apoptotic factor CHOP
was induced only in the si-SMN (20 pmol) condition (Figure 3H).
More importantly, SMN RNAi led to significantly higher nuclear
ATF6 levels in the ISL1+ MNs in a dose-dependent manner (Fig-
ure 3I). The percentage of ATF4+ cells also increased upon SMN
RNAi, with 70% ofMNs co-expressing ATF4 under the severe si-
SMN (20 pmol) condition, compared with 25% of ATF4+ MNs in
si-SMN (10 pmol) treatment and 6% in the si-NT control (Fig-
ure 3J). These results highlight that loss of SMN activates the
ER stress pathway in a dose-dependent manner and affects
MNs more than other cell types.
SMN Overexpression Reduces ER Stress in SMA MNs
We then performed the reciprocal experiment where we investi-
gated whether overexpression of full-length SMN protein would
alleviate the ER stress response in SMAMNs. Using an inducible
lentiviral system to overexpress the full-length SMN cDNA, we
were able to increase SMN protein expression in both type I
and II SMA MNs (Figure 4A). After 3 days, types I and II MNs ex-
pressed 2.6- and 3.2-fold more SMN protein as detected by im-
munostaining (Figures 4B and 4C). Increasing SMN protein in
type I SMA cultures significantly reduced nuclear ATF6 levels
in the HB9+, ISL1+, and ChAT+ MN populations but not in the
non-MNs (Figure 4D). A reduction in the expression of key UPRFigure 3. SMN-Deficient Cells Express Higher Levels of ER Stress Mar
(A) qPCR of FACS-purified HB9+MNs derived fromwild-type and SMA cultures on
stress markers. Only 1-38G MNs show increased expression of markers charact
normalized to GAPDH.
(B) Co-staining of theMNmarker ISL1 (green) and the ER stressmarker ATF6 (red)
of ISL1+ and ISL1 cells were also measured.
(C) Co-staining of the motor neuron marker ISL1 (green) and the ER stress marke
depicts the percentage of ATF4+ cells in whole cultures as well as the percentag
(D and E) Quantification of ISL1+ MNs co-expressing ATF4 (D) and cCASP3 (E) on
increased apoptosis in SMA MNs.
(F) Immunostaining analysis indicating that the majority of MNs undergoing ER s
(G and H) qPCR (G) and western blot analyses (H) showing that knockdown of SM
dependent manner.
(I) Co-staining of ISL1 (green) and ATF6 (red) in wild-typeMNs transfected with no
bars, 50 mm. The increase in nuclear ATF6 intensity upon SMN knockdown is re
(J) Co-staining of ISL1 (green) and ATF4 (red) in SMN knockdown BJ-riPS cultures
and ISL1+ MNs co-expressing ATF4 under SMN knockdown conditions.
Error bars show SD of the mean. *p < 0.05, **p < 0.01, ***p < 0.001. See also Fig
Cellmarkers was also detected with increased SMN expression in
SMA MNs (Figures 4E and 4F). Additionally, the percentage of
ATF4+ MNs was reduced significantly, from 21.4% to 12.9% in
type I cultures and from 10.5% to 4.4% in type II cultures (Figures
4G and 4H), further supporting our findings that the UPR
pathway acts downstream of SMN. Collectively, the gene pertur-
bation studies (Figures 3 and 4) reveal that loss of SMN results in
the induction of ER stress in MNs and that increasing SMN
expression relieves ER stress in SMA cultures.
Changes in Splicing Patterns of the ER Chaperone
DNAJC10 in SMA MNs
Because SMN is an RNA-binding protein that functions in the as-
sembly of spliceosomes and modulates alternative splicing
(Zhang et al., 2008), we wondered whether the elevated ER
stress phenotype associated with SMA is due to aberrant
splicing of mRNA transcripts. To this end, we analyzed our
RNA-seq data for differential splicing events and found 112 sig-
nificant changes in splicing in our purified HB9+ MN population
(Table S2). By RNA-seq, we found that DNAJC10, an important
ER chaperone that maintains normal proteostasis (Ushioda
et al., 2008), showed significant splicing changes in SMA MNs
(Figure S4A). Importantly, Dnajc10 has also been identified pre-
viously to be spliced abnormally in SMA mice (Zhang et al.,
2008). Human DNAJC10 exists as five isoforms: two protein-
coding mRNAs and three pseudogene transcripts (Figure 5A;
Figure S4A). To investigate the splicing of DNAJC10 in wild-
type and SMA MNs, we designed qPCR primers spanning
different regions of the DNAJC10 gene, with one pair of primers
detecting the pseudogenes and the other detecting all five iso-
forms, because specific primers against the protein-coding
mRNAs could not be designed (Figure 5A). By qPCR, we found
that although total (protein-coding mRNAs and pseudogene
RNAs) DNAJC10 transcript levels stayed the same, DNAJC10-
pseudogene levels increased in purified SMA MNs compared
with wild-type MNs (Figures 5B and 5C). This suggested that
DNAJC10 protein-coding mRNAs were reduced, and, because
pseudogenes are non-coding, this resulted in a reduction of
DNAJC10 protein levels in SMN-deficient MNs (Figure 5D). To
confirm that SMN is required for the production of DNAJC10
mRNAs rather than pseudogene RNAs, we evaluated splicing
by qPCR upon overexpression of SMN in type I MN cultureskers
day 31. SMAMNs from 1-38G and 1-51NMNs show a higher expression of ER
eristic of chronic ER stress: PERK, CHOP, and CASP3. Gene expression was
in wild-type and SMAMN cultures. Scale bars, 25 mm. Nuclear ATF6 intensities
r ATF4 (red) in wild-type and SMA MN cultures. Scale bars, 100 mm. The graph
e of ISL1+ MNs co-expressing ATF4.
days 23, 28, and 31, showing increasing ER stress over time, co-incident with
tress (ISL1+ ATF4+ MNs) also co-express ChAT.
N in wild-type BJ-riPS MNs increased UPR target gene expression in a dose-
n-targeting siRNA (si-NT) and SMN siRNA (si-SMN) at the indicated dose. Scale
presented graphically.
. Scale bars, 100 mm. The graph shows the increase in percentage of total cells
ure S3 and Table S2.
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Figure 4. Increasing SMN Expression Reduces ER Stress in SMA MNs
(A) Experimental outline of lentiviral infection to achieve SMN overexpression in type I and II SMA MN cultures. dox, doxycycline.
(B) Quantitative measurement of SMN intensity indicates that SMN expression is 2.6-fold higher upon doxycycline addition in type I MNs and 3.2-fold higher in
type II MNs.
(C) Immunostaining showing SMN overexpression (green) after 3-day induction with 500 ng/ml doxycycline. Cellular nuclei were counterstained with DAPI. Scale
bars, 50 mm.
(D) Quantitative assessment of nuclear ATF6 intensity in various MN populations (HB9+, ISL1+, and ChAT+), with and without doxycycline induction of SMN
overexpression, showing a significant reduction of nuclear ATF6 levels in each of the MN populations. On the other hand, nuclear ATF6 intensity in the non-MNs
remained unchanged.
(E) Overexpression of SMN in type I MN cultures reduces UPR target gene expression, as shown by qPCR.
(F) Western blot showing reduced ER stress markers upon SMN overexpression in type II MNs.
(G) Co-staining of ISL1, SMN, and ATF4 showing fewer ATF4+ cells upon SMN overexpression in type II MN cultures. Scale bars, 100 mm.
(H) Quantification of ATF4+ MNs in type I and II SMA MN cultures upon SMN overexpression.
Error bars show SD of the mean. *p < 0.05, **p < 0.01, ***p < 0.001. See also Table S2.(Figure 4A) and found that pseudogene RNA levels were indeed
reduced significantly upon SMN overexpression (Figure 5E).
Interestingly, loss of DNAJC10 has been recently linked to neu-
rodegeneration in animal models (Mun˜oz-Lobato et al., 2014),
and we wondered whether the reduction of DNAJC10 protein
could contribute to ER stress and MN death, as was the case in
SMA MNs. We then performed siRNA-mediated knockdown of
DNAJC10 in wild-type MN cultures (Figure 5F), which resulted
in elevated ER stress marker expression (Figure 5F) along with
an increased percentage of ATF4+ MNs in DNAJC10-depleted
cultures compared with the non-silencing siRNA control (Fig-
ure 5G). There was also a significant 25% reduction of MNs (Fig-
ure 5H), indicating that reduction of DNAJC10 protein leads to
increased ER stress and contributes to an acceleratedMN death
phenotype. Moreover, in the SMAD7 mouse model, western blot
analysis of spinal cord tissues of mutant animals revealed less
DNAJC10 protein compared with the wild-type animals (Figures
S4B and S4D), further supporting the role of SMN in regulating
DNAJC10 protein levels.
SMA MNs Are More Sensitive to Exogenous ER Stress
Because SMA MNs already have a high basal level of ER stress
signaling, we investigated the possibility that SMA MNs would576 Cell Stem Cell 17, 569–584, November 5, 2015 ª2015 Elsevier Inbe more sensitive to exogenous ER stressors compared with
wild-type MNs. To achieve this, we treated our iPSC-derived
MN cultures for 18 hr with 10 mM tunicamycin, a compound
that blocks N-linked glycosylation of nascent proteins (DuRose
et al., 2006). We observed 20% decrease in total cell number
upon tunicamycin treatment, regardless of genotype (Figures
S5A and S5B). However, SMA MNs are more vulnerable to
tunicamycin stress (55% type I MN loss, p = 0.034, and 50%
type II MN loss, p = 0.042) compared with wild-type cultures
(38% MN loss) (Figure S5B). Notably, the percentage of
SMA and wild-type non-MNs remained unchanged after tuni-
camycin treatment (Figure S5C). This suggests that the MN
degenerative phenotype in SMA is, in part, contributed by an
MN-specific sensitivity to ER stress that is exacerbated by
loss of SMN.
Small-Molecule Inhibitors of ER Stress Rescue SMA
MNs without Increasing SMN Protein
The discovery that SMAMNs are hyper-sensitive to ER stress led
us to investigate whether inhibition of the ER stress pathway
would prevent the degeneration of SMA MNs. To this end,
we first performed RNAi experiments where components of
the ER stress pathway were depleted, and the effects on MNc.
Figure 5. The ER Chaperone DNAJC10 Is Spliced Abnormally in SMA MNs
(A) Schematic showing the five isoforms of DNAJC10 and primers used in this study to distinguish between DNAJC10 pseudogenes (blue) and total DNAJC10
transcripts that detect all five isoforms (red).
(B and C) qPCRmeasuring totalDNAJC10 transcript levels andDNAJC10 pseudogene levels in HB9+ purifiedMNs (B) and ISL1+ purifiedMNs (C), indicating that
SMA MNs express more pseudogene transcripts even though total DNAJC10 levels were unchanged. Notably, type I MNs, which have the least SMN, express
the most DNAJC10 pseudogene transcripts.
(D) Western blot showing that SMA MN cultures express less DNAJC10 protein compared with wild-type MNs. In addition, when SMN is depleted in wild-type
MNs (BJ si-SMN), DNAJC10 protein levels also decreased.
(E) Overexpression of SMN in type I SMA MNs reduces DNAJC10 pseudogene expression without changing total DNAJC10 levels.
(F) Depletion of DNAJC10 by siRNAs in wild-type MNs led to induction of the chronic ER stress markers ATF4 and CHOP.
(G) Knockdown of DNAJC10 in two wild-type lines increased the percentage of ISL1+ MNs co-expressing ATF4.
(H) Depletion of DNAJC10 the reduced number of ISL1+ MNs.
Error bars show SD of the mean. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4.survival were analyzed. ATF6, XBP1, and the ATF4-activated
transcription factor CHOP were depleted significantly by
siRNAs in MN cultures (Figures S5D–S5G). In particular, knock-
down of ATF6 resulted in decreased nuclear ATF6 levels in SMA
MNs (Figure S5G). Perturbation of the ER stress components by
RNAi led to between 30%–50% MN survival in 1-51N MNs (Fig-
ure S5H). In the more severe SMA type I culture, knockdown of
ATF6 or XBP1 led to an approximately 30% increase in MNs,
whereas knockdown of CHOP increased MN survival by 80%
(Figure S5I).
Additionally, we treated iPSC-derivedMN cultures with known
small-molecule inhibitors of ER stress (Table S3): 4-phenylbuty-
rate (PBA), kifunensine (KIF), salubrinal (SAL), guanabenz (GUA),
and GSK2606414 (GSK) at empirically determined doses (Fig-
ure S6).We then assessedMN survival and stress response after
3 days of small-molecule treatment (Figure 6A). We found that in-
hibition of the ER stress pathway by these various small mole-
cules led to greater MN survival compared with DMSO treatment
in SMA type I and II cultures, with SAL and GUA consistently
more effective than the other ER stress inhibitors in promoting
MN survival (Figures 6B and 6C). In addition, treatment of wild-
type cultures with ER stress inhibitors marginally enhanced MN
survival, albeit insignificantly (Figure 6D). This observationCellre-affirms that the ER stress hyper-sensitivity phenotype is spe-
cific to SMA MNs.
Importantly, the small-molecule ER stress inhibitors did not in-
crease cellular SMNprotein in SMA type I and II MN cultures (Fig-
ure 6E), although PBA led to an approximately 25% increase in
full-length SMN mRNA (Figure S5J), as reported previously (An-
dreassi et al., 2004). Rather, these small molecules, particularly
SAL, GUA, andGSK, resulted in attenuation of the UPR pathway,
including downregulation of the pro-apoptotic protein CHOP
(Figure 6E), reduced XBP1 splicing (Figure 6F), and decreased
nuclear ATF6 intensity (Figure 6G). Consequently, the percent-
age of MNs co-expressing cleaved Caspase-3 also decreased
(Figure 6H). This indicates that inhibition of ER stress is sufficient
to prevent MN degeneration in SMA cultures without needing to
elevate SMN protein levels.
Treatment of SMA Motor Neurons with ER Stress
Inhibitors Reverses the Disease Phenotype
We also measured soma sizes of ISL1+/TUJ1+ MNs treated with
ER stress inhibitors and compared them to cultures treated with
DMSO. Although DMSO-treated type I MNs measured approxi-
mately 180 mm2 (Figures 1L and 6I), treatment with ER stress
inhibitors increased soma sizes significantly by at least 10 mm2.Stem Cell 17, 569–584, November 5, 2015 ª2015 Elsevier Inc. 577
Figure 6. Small-Molecule Inhibitors of ER Stress Rescue SMA MNs without Increasing SMN Protein Levels
(A) Experimental outline of ER stress inhibitor treatment on MN cultures. Cultures were treated for 3 days, starting on day 28, and analyzed on day 31.
(B and C) Percentage of ISL1+ MN after ER stress inhibitor treatment in SMA type I (1-38G) (B) and type II (1-51N) (C) cultures. Values were normalized to the
number of MNs plated on day 28.
(legend continued on next page)
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We noticed that SAL and GUA, small molecules that were
most effective in rescuing SMA MNs, also had MNs with the
largest somas (approximately 205 mm2, p < 0.01). Similar results
were also obtained using type II SMA 1-51N motor neurons,
where SAL and GUA were also most effective at increasing
soma sizes (p < 0.05) (Figures 6J and 6K). Notably, SAL- and
GUA-treated SMA MNs measured approximately 210 mm2,
very similar to wild-type MNs (measuring approximately
220 mm2) (Figure 1L).
GUA Alleviates ER Stress and Preserves Ventral Horn
MNs in SMAD7 Mice
Next, we questioned whether elevated ER stress is also
observed in SMAD7mice andwhether ER stress inhibition would
promote SMAMN survival in vivo. The SMAD7 mouse displays a
relatively severe decrease in average lifespan, concurrent with
early impairment of motor behavior correlating with fewer spinal
MNs (Le et al., 2005). By immunoblotting, we compared the
expression of UPR markers of spinal cords from late symptom-
atic SMAD7 mice at post-natal day (P) 12 to their wild-type
(WT) littermates. Consistent with the in vitro results, we observed
increased levels of cleaved Atf6 and Chop in the SMAD7 spinal
cords (Figure 7A), confirming elevated ER stress in SMA MNs
in vivo. We then analyzed the effect of ER stress inhibition on
SMAD7 mice.
In vitro analyses indicate that GUA, an inhibitor of eIF2a
dephosphorylation (Tsaytler et al., 2011), was most effective in
the rescue of SMA MNs (Figure 6). Moreover, GUA penetrates
the blood-brain barrier (Meacham et al., 1981), making it an ideal
ER stress inhibitor to test in vivo. To investigate the effects of
GUA treatment on SMA mice, we administered 4 mg/kg GUA
by subcutaneous injections (Tribouillard-Tanvier et al., 2008)
into pre-symptomatic P2 mice twice daily. First, to determine
whether GUA was able to reduce UPR markers in the spinal
cords of SMAD7 mice, we performed qPCR and immunoblotting
on spinal cord sections from fully symptomatic P8 mice after
they were treated with either GUA or DMSO. SMAD7 mice
treated with GUA had significantly higher levels of phospho-
eIF2a, confirming that GUA was able to cross the blood-brain
barrier and retain its function in the spinal cord (Figures S4B
and S4C). We found that SMAD7 mice that received twice daily
GUA doses had reduced expression of the UPR transcripts Ire1,
Chop, Atf4, and Pfdn5 to levels similar as those in wild-typemice
(Figure 7B). Furthermore, GUA-treated SMAD7 mice also had
reduced Caspase-3, Caspase-4, and Caspase-12 expression
similar to wild-type mice (Figure 7C). Importantly, Caspase-4
and Caspase-12 are activated in response to ER stress (Hitomi
et al., 2004; Kim et al., 2006; Nakagawa et al., 2000). GUA treat-
ment also led to a 3-fold increase inChATmRNA compared with(D) Percentage of ISL1+ MNs after ER stress inhibitor treatment in wild-type (BJ)
(E) Western blot of type I MN cultures treated with the various ER stress inhibitor
reduced.
(F) Spliced XBP1 assay performed on SMA type I MN cultures treated with DMS
(G) Measurement of nuclear ATF6 intensity in SMA type I MN cultures treated wi
(H) Quantification of cleaved Caspase3+ MNs in SMA type I MN cultures treated
(I and J) ER stress inhibitor treatment increases the soma size of type I (I) and ty
(K) Representative images of type I SMAMN cultures treated with DMSO, SAL, or
shown at the bottom. The white dotted outlines represent the measured soma s
Error bars show SD of the mean. *p < 0.05, **p < 0.01. See also Figures S5 and
CellDMSO-treated SMA animals. Taken together, the qPCR results
suggest that ER stress-mediated apoptosis is inhibited in spinal
MNs of GUA-treated SMA mice, possibly leading to MN preser-
vation. Western blot analysis of spinal cord sections confirmed
our qPCR results. Although GUA does not change Smn protein
levels in spinal cords of treated animals, we observed a reduc-
tion in the UPR markers cleaved Atf6, Chop, Caspase-4, and
Caspase-12 along with an increase in the MNs markers ChAT
and Smi-32 in treated animals (Figure 7E).
To confirm the preservation of spinal cordMNs in GUA-treated
animals, we analyzed 20 lumbar sections of each P8 mouse (4–
5 animals/condition), representative of the entire lumbar spinal
cord, and counted the number of ChAT+MNs in the ventral horns
(Figure 7F). On average, DMSO-treated SMAD7 animals had
fewer MNs compared with DMSO-treated wild-type animals
(13.5 versus 22.7 ChAT+MNs/10-mmsection, p = 0.0028), similar
to previous reports (d’Errico et al., 2013; Mentis et al., 2011).
Importantly, we observed that GUA treatment increased the
number of ChAT+ MNs by an average of 40% (± 5%) in
SMAD7 animals compared with DMSO-treated animals (p =
0.034; Figure 7G), indicating that GUA prevents the degeneration
of spinal MNs by inhibition of ER stress.
Previous studies have shown that MN soma sizes are signifi-
cantly smaller in SMAD7 mice as early as P4 (d’Errico et al.,
2013), suggesting that MNs are undergoing atrophy, and large
MNs are lost even when the animals are pre-symptomatic. We
also found that DMSO-treated SMAD7 MNs were significantly
smaller than DMSO-treated wild-type MNs (220 ± 25 mm2 in
SMA and 316 ± 27 mm2 in the WT, p = 0.0092). Importantly,
ChAT+ MNs of SMAD7 animals treated with GUA were larger
(296 ± 28 mm2, p = 0.0277), similar to the sizes of wild-type
MNs, suggesting the presence of healthier MNs in GUA-treated
SMAD7 animals (Figure 7H). Consequently, GUA treatment led
to an approximately 30% increase in the lifespan of SMA ani-
mals, from a maximum of 13 days (median = 10 days) to
17 days (median = 13 days) (Figure 7I).
Because of MN loss in SMA mice, denervation of neuromus-
cular junctions (NMJs) is evident in vulnerable muscle groups
(d’Errico et al., 2013; Le et al., 2005). This led to motor deficits
in SMA mice that resulted in their inability to right. We measured
righting reflex times of DMSO- and GUA-treated mice at P8
before the mice were sacrificed and found that GUA treatment
significantly reduced the righting reflex time of SMA mice (Fig-
ure 7J). An analysis of the hindlimb muscles of P8 mice revealed
that GUA treatment prevented the denervation of NMJs in SMA
mice (Figure 7K), with approximately 60% of hindlimb NMJs
remaining innervated compared with 42% of innervated NMJs
(p = 0.0125) in DMSO-treated SMA mice. Collectively, these re-
sults indicate that inhibition of ER stress by GUA led to theMN cultures. The values were not significant.
s, indicating that SMN levels remained the same, whereas CHOP protein was
O, ER stress inhibitors, and 1 mM tunicamycin (TM) as a positive control.
th the indicated compound.
with the indicated compound.
pe II (J) SMA MNs.
GUA and stained with ISL1 and TUJ1. Magnified images of the white boxes are
izes.
S6 and Table S1.
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Figure 7. Guanabenz Reduces the UPR in Spinal Cords of SMA Mice and Increases Ventral Horn MN Survival
(A) Immunoblotting of spinal cord lysates from four SMAD7 mice and three wild-type mice on P12. Spinal cords from SMAD7 mice showed low expression of the
full-length SMN protein and higher levels of the UPR markers cleaved Atf6 and Chop. Error bars show SD of the mean.
(B) GUA treatment results in a reduction of Ire1,Chop, Atf4, and Pfdn5mRNA expression in spinal cords of SMAD7 mice to levels similar as those in control wild-
type mice. Error bars show SD of the mean.
(legend continued on next page)
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preservation of spinal MNs in vivo, which was accompanied by
an improvement in the lifespan andmotor ability of SMAD7mice.
DISCUSSION
Directed differentiation of patient-derived iPSCs holds great
promise in understanding neurodegenerative diseases such as
SMA that affect selective neuronal populations. However, differ-
entiation into specific neuronal subtypes is not always efficient,
and gene expression profiling and other types of studies carried
out using mixed cultures can mask important cellular events
taking place in the neuronal population of interest. Because
surface markers specific to MNs and many other types of
neurons have not yet been established, we circumvented
the MN purification problem by isolating cells based on their
unique transcription factor expression for deep transcriptome
sequencing.
One of our key findings is that SMA MNs show a hyper-sensi-
tivity to ER stress, and this is caused by increased activation of
UPR genes in response to SMN deficiency. This activation is
more pronounced in MNs than non-MNs, presumably because
MNs already possess basal ER stress signaling (Kiskinis et al.,
2014), and additional activation is more likely to surpass the
threshold level the cell can withstand without committing to
apoptosis. We also identified that abnormal splicing of a key
ER chaperone, DNAJC10, contributes, in part, to the elevated
ER stress phenotype observed in SMN-deficient MNs.
Furthermore, our cell culture-based model of SMA accurately
predicted in vivo results in SMAD7 mice. Importantly, we
observed increased activation of ER stress markers in spinal
cords of SMA mice. GUA, the ER stress inhibitor that was most
effective in vitro, also preserved MN numbers and size in SMA
mice. Notably, we also tested PBA on our SMA iPSC-derived
MNs and noticed a lack of efficacy in vitro. PBA has been iden-
tified previously as a drug for clinical trials on SMA patients but
failed in phase II because of a lack of efficacy. This would have
been predicted by our cell culture model system.
As a proof of concept that inhibition of ER stress is important
for SMAMN survival, SMAmice treated with GUA demonstrated(C) Decreased Caspase-3 expression as well as ER stress-associated Caspase-
mice treated with GUA. Error bars show SD of the mean.
(D) Although mRNA levels of Smn remained low in SMAD7 animals, expression of
the mean.
(E) Western blot analysis of spinal cord lysates of SMAD7 and wild-type mice
expression but led to an increase in the MN markers Smi-32 and ChAT. Error ba
(F) Representative images of ventral horn ChAT+ MNs (red) of the treated animal
(G) Quantification of the number of ChAT+ MNs in the ventral horns of each 10-mm
the entire lumbar spinal cord were analyzed. Error bars show mean ± SEM.
(H) Measurement of soma sizes of ChAT+ ventral hornMNs indicating that the aver
of DMSO-treated SMAD7 animals. Error bars show mean ± SEM.
(I) Kaplan-Meier survival curve of SMAD7 mice treated with either DMSO (n = 9)
treatment (p = 0.0122). Error bars show SD of the mean.
(J) Righting reflex time of DMSO- and GUA-treated mutant and wild-type animals
reflex compared with DMSO controls (p = 0.033). Error bars show SD of the mea
(K) NMJs of hindlimb muscles stained with a-bungarotoxin (BTX). Neurofilamen
treated SMAD7mice, whereas the same region in GUA-treated SMAD7 animals sh
images of the white boxes are shown at the bottom. Scale bars, 100 mm. Error b
(L) Analysis of the innervation status of hindlimb NMJs in treated mice. NMJs ar
NMJs. GUA treatment in SMA mice led to a 20% increase in innervated NMJs (p
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4 and Table S3.
Cellreduced spinal cord UPR marker expression along with
improved spinal MN survival and motor function and a modest
increase in lifespan. Because MNs are particularly susceptible
to ER stress, it is unlikely that treatment with drugs like GUA
will alleviate all of the systemic defects caused by SMN defi-
ciency. Notably, a prior study has shown that increasing SMN
in motor neurons alone in a severe SMA mouse model
(SMN2+/, Smn2B-Neo/2B-Neo) preserved MNs but also had a
maximum lifespan of 16 days (median = 12 days) (Gogliotti
et al., 2012), very similar to what we found in our GUA-treated
SMAD7 mice, which survived for a maximum of 17 days (me-
dian = 13 days). Therefore, neuroprotection alone, achieved
either by reducing ER stress or restoring SMN expression only
in MNs, is unlikely to be sufficient to correct all of the defects
found in children with SMA. Other studies also indicate that
increasing SMN expression in the CNS alone (MNs and non-
MNs) was able to extend the lifespan of SMAD7 mice to
30 days (Hua et al., 2011), whereas restoration of SMN expres-
sion to peripheral tissues alone was sufficient for long-term
rescue of SMA mice for more than 300 days (Hua et al., 2011,
2015). Taken together, our results support our view that
increased ER stress is a pathway that explains why MNs, but
not other cells, are affected by low levels of SMN and that
reducing ER stress does not correct systemic aspects of the
SMA phenotype. It will be important to identify pathways that
mediate the dysfunction seen in other tissues with low levels of
SMN.
In conclusion, transcriptome profiling of purified cell popula-
tions opens a new avenue for understanding disease mecha-
nisms. Using this strategy, we found ER stress hyperactivity
and a hyper-sensitivity phenotype associated with SMA MNs.
Small-molecule inhibition of ER stress rescued SMA MNs
in vitro and in vivo, with treated mice showing improved motor
function and a modest increase in lifespan. Our current work
serves as proof of principle that targeting disease phenotypes
identified in vitro using patient iPSCs accurately predicts dis-
ease-related outcomes even in vivo and may be used as a strat-
egy to understand other neurodegenerative diseases showing
cell-type-specific vulnerability.4 and Caspase-12 expression was observed in spinal cord lysates of SMAD7
the MNmarker ChAT increased in GUA-treated animals. Error bars show SD of
treated with either DMSO or GUA, showing that GUA reduced UPR marker
rs show SD of the mean.
s. Scale bar. 100 mm. Error bars show SD of the mean.
section. 4–6 animals from each condition and 20 lumbar sections representing
ageMN size of SMAD7 animals treatedwith GUA is significantly larger than that
or GUA (n = 8). Survival increased by approximately 35% (4 days) upon GUA
indicating that GUA-treated SMAD7 mice have a significantly reduced righting
n.
ts are identified by Smi-32 staining. Denervated NMJs are evident in DMSO-
owed preservation of NMJ innervation, similar to a wild-type animal. Magnified
ars show SD of the mean.
e scored as innervated when there is Smi-32 staining of neurofilaments at the
= 0.0125). Error bars show SD of the mean.
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EXPERIMENTAL PROCEDURES
Human iPSC Culture and MN Differentiation
Two wild-type human iPSC lines, BJ-riPS (Warren et al., 2010) and 18a (Boult-
ing et al., 2011), a type I SMA patient-specific iPSC line (1-38G), and a type II
SMA iPSC line (1-51N) were cultured routinely on Matrigel-coated dishes in
MTeSR medium (STEMCELL Technologies). MNs were differentiated as
described previously (Amoroso et al., 2013) with slight modifications (Supple-
mental Experimental Procedures).
Purification of MNs by MARIS for Gene Expression Analysis
Day 28MNcultures were dissociated into single cells using Accutase and fixed
in 4%paraformaldehyde (PFA). HB9 antibody (Developmental Studies Hybrid-
oma Bank, 81.5C10) was diluted 1:100 in blocking buffer (1% BSA) and 0.2%
saponin (Sigma) in PBS supplemented with 50 U/ml Superase.In (Ambion) and
incubated with the cell suspension for 3 hr. Alexa Fluor 488-conjugated sec-
ondary antibody was diluted 1:1,000 in blocking buffer and incubated with
the cell suspension. The cells were then washed with Dulbecco’s PBS
(DPBS) before FACS on BD FACS Aria. Sorted cells were treated with Protein-
ase K for 1 hr at 50C before addition of Trizol LS (Invitrogen) for RNA extrac-
tion. DNase treatment using Turbo DNA-free (Ambion) was performed to
remove contaminating genomic DNA.
mRNA-Seq Library Preparation and Sequencing
Illumina mRNA-seq libraries were prepared using the TruSeq RNA kit using
200 ng of total RNA. Library sequencing was carried out on an Illumina MiSeq
with four samples from both conditions pooled together, with each library
sequenced up to a depth of 30 million fragments using a 100-bp paired-
end flow cell. RNA-seq readsweremapped using TopHat version 2.0.9 against
the human genome build hg19. Details of the RNA-seq analyses are provided
in the Supplemental Experimental Procedures. The data are available at GEO:
GSE69175.
cDNA Synthesis and PCR
qPCR analyses on cDNA transcribed with a high-capacity cDNA reverse tran-
scription kit were performed on the QuantStudio 12K Flex system using FAST
SYBR master mix (all from Applied Biosystems) and normalized to GAPDH or
ACTB expression. A list of human primers is provided in Table S4, and mouse
primers are listed in Table S5.
RNAi
MN cultures were seeded at 50,000 cells/well in a 96-well plate. Non-target-
ing siRNA or siRNA against human SMN (Santa Cruz Biotechnology) were
complexed with Lipofectamine RNAiMAX (Invitrogen) following the manufac-
turer’s instructions. To enhance the knockdown efficiency for a period of
7 days, a second transfection was repeated 3 days after the initial
transfection.
SMN Overexpression
The full-length SMN1 cDNA was cloned into the doxycycline-inducible
pTRIPZ lentiviral construct (OpenBiosystems) with a puromycin selection
marker. The control was a red fluorescent protein (RFP) cDNA. Lentiviral
particles were made and concentrated. Day 23 MN cultures were infected
with either SMN lentiviral particles or RFP lentiviral particles in the presence
of 8 mg/ml polybrene. Puromycin (500 ng/ml) selection and 500 ng/ml doxy-
cycline treatment, where applicable, were pursued for 3 days before the
cells were harvested for RNA and protein or fixed for immunostaining
(Figure 4A).
Small-Molecule Treatment
Tunicamycin (Calbiochem), sodium-4-phenylbutyrate (EMD Millipore),
kifunensine (Tocris), salubrinal (Calbiochem), guanabenz acetate (Tocris
Bioscience), and GSK2606414 (EMD Millipore) were reconstituted in DMSO
and diluted in MNmedia at the desired concentrations. Sodium-4-phenylbuty-
rate was used at 2 mM (Qi et al., 2004). For the other compounds, a dose-
response assay was performed to determine the most effective concentration
for in vitro experiments (Figure S6).582 Cell Stem Cell 17, 569–584, November 5, 2015 ª2015 Elsevier InImmunostaining
Cellswere fixed in 4%PFA, permeabilizedwith 0.1%TritonX-100, andblocked
with buffer consisting of 5% fetal bovine serum (FBS) and 1%BSA. The primary
antibodies used in this study (and their respective dilutions) were as follows:
rabbit ISL1 (Abcam, catalog no. ab109517, 1:1,000), mouse TUJ1 (Covance,
catalog no. MMS-435P, 1:1,000), mouse HB9 (Developmental Studies Hybrid-
oma Bank [DSHB], catalog no. 81.5C10, 1:200), mouse ISL1 (DSHB, catalog
no. 39.4D5), mouse SMI-32 (Calbiochem, catalog no. NE-1023, 1:1,000),
goat ChAT (Millipore, catalog no. AB114P, 1:100), rabbit ATF6 (Abcam, catalog
no. ab37149, 1:500), rabbit ATF4 (Cell Signaling Technology, catalog no.
11815, 1:100), rabbit cleaved Caspase-3 (Cell Signaling, catalog no. 9661),
and mouse monoclonal SMN (BD Pharmingen, 1:250). Cellular nuclei were
counterstained with 0.5 mg/ml 40,6-diamidino-2-phenylindole (DAPI).
Image Acquisition and Analysis
Fluorescent images were acquired with an automated microscope (Perki-
nElmer Operetta) at 203 magnification. Image analysis was performed using
Columbus software (PerkinElmer) by first recognizing and outlining cellular
nuclei based on DAPI. MNs were identified based on ISL1 expression, and nu-
clear intensities of ATF6 or ATF4 were measured. Because there is basal
expression of nuclear ATF6 in MNs, we measured the relative intensities of
average nuclear ATF6 per MN and normalized the intensity with wild-type cul-
tures. ATF4 is not expressed basally, and we took the intensity cutoff of >150
to define a positive stain.
For soma size analysis, cellular nuclei were identified by DAPI, and the cyto-
plasmic area surrounding the nucleus was determined based on TUJ1 stain-
ing. The soma size area was measured based on the cytoplasmic area
surrounding the nucleus, excluding neuronal projections (Figure 1K).
Western Blot Analysis
Cells or tissue sections were lysed in radioimmunoprecipitation assay (RIPA)
buffer (Sigma) with protease inhibitor (Roche) and a phosphatase inhibitor
cocktail (Santa Cruz). Samples containing 25 mg of protein were boiled in
Laemmli buffer and resolved on 10% Tris-glycine polyacrylamide gels. Pro-
teins were transferred to polyvinylidene fluoride (PVDF) membranes, blocked
with 5% milk, and incubated overnight with primary antibodies as follows:
mouse SMN (BD Pharmingen, 1:1,000), rabbit ATF6a (Abcam, catalog no.
ab37149, 1:500), mouse CHOP (Santa Cruz, catalog no. sc-7351, 1:100), rab-
bit GAPDH (Abcam, catalog no. ab9485, 1:2,000), rabbit a-tubulin (Abcam,
catalog no. ab126165, 1:2,000). The blots were then incubated with respective
HRP-conjugated antibodies at 1:2,000 dilution.
Animals and Drug Administration
All animal studies were approved by the Harvard University Institutional Animal
Care and Use Committee and performed in accordance with institutional and
federal guidelines. FVB mice were obtained from Charles River Laboratories.
The original breeding pair of heterozygous SMND7 mice (mSmn+/–;SMN2+/+,-
SMND7+/+) on the FVB background were provided by The Jackson Labora-
tory. Guanabenz was resuspended in DMSO at 10 mg/ml as a stock solution
and diluted in 10% (2-hydroxypropyl)-b-cyclodextrin immediately before
administration at 4 mg/kg via subcutaneous injections starting at P2. Animals
received doses twice daily (injections 8 hr apart) and were euthanized at P8.
The spinal cords were dissected, cervical regions were homogenized in
RIPA buffer for western blot, lumbar regions were collected for immunostain-
ing, and thoracic regions were utilized for RNA expression studies. Hindlimb
muscles were dissected and embedded in optimal cutting temperature
(OCT)-sucrose for cryostat sectioning.
Statistical Analyses
In vitro studies were performed in four independent experiments (biological
replicates) with six to ten independent wells (technical replicates) unless stated
otherwise. Student’s t test was performed to assess statistical significance.
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